Evoralis is developing innovative enzymes that can break down even the toughest mixed and blended fibers, paving the way for a truly circular economy in textiles. Evoralis, a pioneering company specializing in the discovery and development of plastic-depolymerizing enzymes, has raised £2.5M in a Seed funding round. This investment marks
Agreement foresees creation of a joint stock company in which EIB and LIFTT will each invest €50 million. Around 20 to 30 equity investments envisaged primarily in Italian companies, focusing on sectors including life sciences, deeptech and cleantech. The European Investment Bank (EIB) and Italian venture capital firm LIFTT are
In the emerging landscape of innovative medical therapies, radiopharmaceuticals represent a promising frontier in the treatment of many diseases, particularly oncological diseases. These therapeutic and diagnostic agents, which contain radioactive isotopes, are used to diagnose and treat various diseases, including several types of cancer. The effectiveness of radiopharmaceuticals is based
Mattia Perroni, CEO Medicilio An economics graduate from Bocconi University, but always passionate about software and innovation, Mattia Perroni started his career as a private equity consultant, mainly in the pharmaceutical sector, working in London and Milan. After five years at Rocket Internet, he became Country Manager for
Touch Sensity: “making materials talk“ Predictive maintenance aims to reduce costs to increase the competitiveness of companies by avoiding unplanned production downtime while increasing the useful life of industrial machinery (e.g. reducing plant downtime by 5-15%). The technology combines sensor data with analytical techniques to enable optimised maintenance planning by
Francesco Lo Cascio, LIFTT Project Manager How and where did the Touch Sensity project come about? “It is a French company – explains the Project Manager – based in Bordeaux, which specialises in assessing the quality of materials and monitoring their structural characteristics, particularly when they are used
Milan, June 6, 2024 – BetaGlue™ Therapeutics (“BetaGlue” or the “Company”) a clinical-stage radiotherapy company developing novel products for the personalised treatment of solid tumour cancers today announces the closing of an €8m equity financing round. The round included both existing and new investors and was led by Neva SGR S.p.A.,
Evergreen Theragnostics, a clinical-stage radiopharmaceutical company, today announced the successful completion of a $26M capital raise supported both by existing shareholders and new institutional investors, Petrichor and LIFTT. The financing advances Evergreen’s novel discovery pipeline into clinical trials, supports commercialization of its diagnostic agent, and further expands CDMO capabilities to
VAT n. 12013790014
Shared Capital
€ 100.835.954,00 authorised,
€ 60.223.243,00 paid,
€ 60.223.243,00 as per last statutory financial statements.
LIFTT S.p.A. adopts an Organization, Management and Control Model in line with the provisions of Legislative Decree 231/2001, and the Code of Ethics as completing part of the Model.